Severity
Moderate
CPSC recall · Reported March 18, 2021
The bottles containing the prescription drug can leak due to a fit issue between the press-in bottle adapter and bottleneck. If the bottle is leaking, there is a risk of drug expo…
Genentech, a member of the Roche Group, of South San Francisco, Calif. recalled This recall involves bottles of the prescription drug Evrysdi, a prescription medicine us… — a moderate-severity action.
Genentech Recalls Prescription Drug Evrysdi Due to Failure to Meet Child Resistant Packag… was recalled by Genentech, a member of the Roche Group, of South San Francisco, Calif. in March 18, 2021. Reason: The bottles containing the prescription drug can leak due to a fit issue between the press-in bottle adapter …. Remedy: Consumers should immediately store Evrysdi in a safe location out of reach and sight of c…. Verify recall #21729 with the CPSC before acting.
The recall
Genentech, a member of the Roche Group, of South San Francisco, Calif. issued this moderate-severity CPSC recall — The bottles containing the prescription drug can leak due to a fit issue between the press-in bottle adapter ….
Sourced from official CPSC enforcement records. Verify recall #21729 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This CPSC action (record #21729) was formally reported on March 18, 2021. It is classified under Moderate severity, with a current status of Active. Genentech, a member of the Roche Group, of South San Francisco, Calif. is listed as the recalling firm. Federal records list the affected scope as About 14,000.
The documented reason for this recall is: The bottles containing the prescription drug can leak due to a fit issue between the press-in bottle adapter and bottleneck. If the bottle is leaking, there is a risk of drug exposure by contact with skin or eyes. Presc… Distribution information was not included in the agency filing, so consumers should assume broad potential exposure until the firm publishes point-of-sale details. The remedy documented by the agency is: Consumers should immediately store Evrysdi in a safe location out of reach and sight of children. Consumers should inspect the bottle for any leaking. If it is leaking, contact Genentech for a free r… — consumers holding this product should act on that instruction rather than relying on general guidance.
Within the same product category the archive holds 6 closely related recalls — clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category — 14,048 drugs & medications recalls on record
Of 100,165 recalls in the database, 23,668 are high severity, 72,097 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger — we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
About 14,000
Related Recalls
6
0 from same agency
This recall involves bottles of the prescription drug Evrysdi, a prescription medicine used to treat spinal muscular atrophy (SMA) in adults and children 2 months of age and older. The recalled 100 mL amber bottles have "Evrysdi (risdiplam) for oral solution," the dosage and "NDC 20242-175-07" on the front of the bottle labels.
The bottles containing the prescription drug can leak due to a fit issue between the press-in bottle adapter and bottleneck. If the bottle is leaking, there is a risk of drug exposure by contact with skin or eyes. Prescription drugs must be in child resistant packaging that prevents children from gaining access to the contents as required by the Poison Prevention Packaging Act (PPPA).
Consumers should immediately store Evrysdi in a safe location out of reach and sight of children. Consumers should inspect the bottle for any leaking. If it is leaking, contact Genentech for a free replacement. Consumers can continue to use as directed, as the leakage is not anticipated to impact the safety or efficacy of administered medicine. If Evrysdi gets on your skin, wash the area with soap and water. If Evrysdi gets in your eyes, rinse your eyes with water. Genentech is contacting all known purchasers directly.
| Attribute | Value |
|---|---|
| Agency | U.S. Consumer Product Safety Commission |
| Severity class | Moderate |
| Status | Active |
| Recall number | 21729 |
| Date reported | March 18, 2021 |
| Date initiated | March 18, 2021 |
| Recalling firm | Genentech, a member of the Roche Group, of South San Francisco, Calif. |
| Affected scope | About 14,000 |
| Distribution | Not disclosed |
| Official source | CPSC notice → |
Profile values are sourced directly from the official CPSC enforcement record. Source: U.S. Consumer Product Safety Commission.
What to do with this recall
Consumers should immediately store Evrysdi in a safe location out of reach and sight of children. Consumers should inspect the bo…
This page summarizes the official CPSC record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Keep tracking product safety across the federal recall archive.
Recall Checker
Search the full archive by product name, brand, or recall number across every agency.
Check a product →
CPSC recalls
Every recall issued by CPSC, newest first.
Browse the feed →
RecallRadar
Live feed of the latest recalls across the FDA, CPSC and NHTSA — filter by agency and severity.
View the live feed →
Rankings
The largest recalls by units affected and the most-recalled product categories.
See the rankings →
Browse by category
Find recalls by product type to spot recurring defect patterns.
All categories →
What to do next
A step-by-step guide to refunds, repairs, and returns after a recall.
Read the guide →
Other recalls in the same product category — useful for spotting patterns across the same defect class or manufacturer.
AVEVA Drug Delivery Systems, Inc. · 2026-06-03
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Compare this recall with Nicotine Transdermal System Patch, 14 mg, 14 patches per bo… →
Source: FDA, CPSC, and NHTSA federal recall databases. This recall: CPSC, reported March 18, 2021.
Recall information is sourced from official federal agency databases. Always verify recall details with the issuing agency for the most current status. This information is for research and awareness purposes only.
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records — no number is typed in by an editor. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of June 2026.